Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2740
Full Text
Open PDFAbstract
Available in full text
Date
February 15, 2019
Authors
Publisher
American Association for Cancer Research (AACR)